Lobbying registration dated 2026-02-13
Registrant: Danielle Flieler
Client: GlaxoSmithKline Inc.
Targeted institutions:
Canadian Heritage (PCH)
Justice Canada (JC)
Treasury Board Of Canada Secretariat (TBS)
Prime Minister's Office (PMO)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Indigenous Services Canada (ISC)
Public Health Agency of Canada (PHAC)
Patented Medicine Prices Review Board (PMPRB)
Senate of Canada
Health Canada (HC)
Government funding received:
Lobbying activity details:
Sharing information with government and Members of Parliament on different models for national pharmacare, specifically as it relates to access to medicines.
The Government of Ontario has passed legislation requiring the public disclosure of payments made to Health Care Providers and Health Care Organizations by the broader health care industry, including pharmaceutical companies, generic manufacturers, and medical device companies. GlaxoSmithKline seeks to advocate for a national approach to disclosure through either the support of similar provincial initiatives, coordinated action through the Federal / Provincial and Territorial meetings of the Ministers of Health, and / or the establishment of national requirements.
Engage government officials regarding domestic manufacturing of seasonal and pandemic flu vaccine.
Antimicrobial Resistance (AMR) - Identification of the need for a multi-sectoral stakeholder working group to pursue joint goals under a Pan-Canadian AMR strategy and to strengthen Canada's end-to-end research capacity in AMR.
Renewal of national vaccine strategy to close gaps in vaccination coverage for Canadians, especially among seniors.
Reforms to the Patented Medicines Review Board (PMPRB), whose guidelines seek to ensure a balance between the prices set by manufacturers for patented medicines sold in Canada and the maintenance of an attractive environment for pharmaceutical research and development. Specifically with regard to ensuring that any actions and proposed changes by the PMPRB do not negatively impact access to patented medicines in Canada.
Raise awareness regarding the potential risks to drug and vaccine supply for Canadian patients arising from new U.S. state-level reimportation legislation.
Seek funding and support for pilot projects making anti-infective medications available to equity seeking populations, helping to combat AMR.
Participation in consultations regarding the Digital Charter and the federal government's plans to overhaul Canada's privacy regime, to enable the use of anonymized health data for new medication research and development.
Input on the work of the Advisory Committee on the Implementation of National Pharmacare, specifically as it relates to access to medicines.
Engaging Health Canada on the Self-Care Products Initiative as it pertains to plain language labelling and a risk-based approach to regulatory oversight for non prescription drugs.
Ensure the National Advisory Committee on Immunization has sufficient resources to undertake timely reviews of new vaccines that are made available to the Canadian marketplace.
Engage with government to strengthen the Priority Review of Drug Submissions process.